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Objective. Oxidative stress is considered to be the main factor in the development of diabetic complications and tissue injury.
our objective was to investigate and compare the oxidant/antioxidant conditions and detoxiﬁcation mechanisms of the liver, lung,
kidney,cardiactissues,andmitochondriaofratswithdiabetesinducedbystreptozocin(STZ).Methods.Ratswithdiabetesinduced
by streptozocin were anesthetized by administering 90mg/kg ketamine hydrochloride and 3mg/kg xylazine hydrochloride.
Thoracic cavities were incised open; liver, lung, kidney, and cardiac tissues were removed and stored at −70
◦C. All samples were
homogenized and mitochondrial fractions were separated. Total Antioxidant Status (TAS), Total Oxidant Status (TOS), Oxidative
StressIndex(OSI),Paraoxonase(PON),Arylesterase,Catalase(Cat),Malondialdehyde(MDA),andGlutathion-S-transferasewere
measured in each fraction. Results. MDA and TOS levels were signiﬁcantly increased in liver tissues, and TOS and OSI were
increased in the mitochondrial fractions of diabetic rats. These increases were not statistically signiﬁcant compared to the control
group. No signiﬁcant diﬀerences were determined in the antioxidant and GST activities. Conclusion. According to our results,
oxidative stress has not developed in rats with diabetes induced by streptozocin. The detoxiﬁcation system was induced; however,
this induction did not diﬀer signiﬁcantly from the controls.
1.Introduction
Diabetes is a rapidly spreading disease due to current adverse
living conditions and unbalanced nutrition habits. The in-
cidence and prevalence of type II diabetes are increasing
particularly in industrializing and developing nations, and
this increase is estimated to exceed 200 million as of the
end of 2011 [1]. Chronic complications of diabetes aﬀect
several organ and systems creating the primary causes of
morbidity and mortality. Overall, chronic complications are
grouped into two categories as vascular and nonvascular
complications [2–4].
Diabetes is a metabolic disease; however, it has long been
known that its complications are associated with oxidative
stress[5].Chronichyperglycemialeadstoincreasedoxidative
stress particularly in tissues where complications of diabetes
develop [6]. The mechanisms that increase oxidative stress
in diabetes include nonenzymatic glycation, autooxidative
glycation, metabolic stress secondary to the changes in en-
ergy metabolism, activity of the sorbitol pathway, levels of
inﬂammatorymediators,andtissueinjuryresultingfromthe
changes in antioxidant defense system [7–13].
In this study, our objective was to investigate and com-
pare the antioxidant-oxidant systems (TAS,TOS, OSI, PON,
Arylesterase, Catalase, and MDA) and levels of GST enzyme
that plays an important role in detoxiﬁcation mechanisms
in heart, liver, lung, and kidney tissues and mitochondrial
fractions in rats with hyperglycemia (not chronic) developed
with STZ, a diabetogenic chemical agent.
2.MaterialandMethods
2.1. Development of Experimental Diabetes. Twelve female
and male Wistar albino rats of 250–300 grams in weight,2 Experimental Diabetes Research
reproduced in the Experimental Animals Laboratory of
Cumhuriyet University, Medical Faculty were used in this
study. Rats were separated into two groups as control and
study groups and were provided with free access to food
and water. An approval document dated November 1st; 2007
and numbered B.30.2.CUM.0.01.00.00-50/214 was obtained
from the Cumhuriyet University, Experimental Animals
Ethics Committee.
B l o o dg l u c o s el e v e l so fr a t sw e r em e a s u r e df o l l o w i n g
and overnight fasting (Lever Check TD-4222). Rats with
blood glucose levels 80–110mg/dL were considered normal.
A single dose of intraperitoneal 60mg/kg streptozocin (STZ;
Sigma Chemical Co., St. Louis Missouri, USA) resolved in
0.1M citrate buﬀe ro f4 . 5p Hw a su s e dt od e v e l o pd i a b e t e si n
the experimental group of animals without sex distinction.
Blood glucose levels were measured in the intravenous blood
samples obtained from the tails of rats at 48 hours of strep-
tozocin injection. Rats with blood glucose levels of 250mg/
dL were considered diabetic.
2.2. Surgical Procedure. All rats were anesthetized at week
two with an intramuscular injection of 90mg/kg ketamine
hydrochloride, 3mg/kg of xylazine hydrochloride into left
fore leg muscle. Thoracic cavities were incised open; liver,
lung, kidney, and heart tissues were removed and stored at
−70◦C.
2.3. Mitochondria Extract. All defrosted tissues were homog-
enized in ice shower containing 4mL of 0.2M phosphate
buﬀerat pH 7.4. Homogenates werecentrifugedat 3000g for
15 minutes at 4◦C to remove tissue remnants. Activities were
determined in the supernatant.
Mitochondria were extracted according to the method
deﬁnedbyMaxetal.[14]andmodiﬁedbyMousa[15].Sam-
ples of 1 gram was obtained from each tissue and homog-
enized in 5mL of 0.25M sucrose solution. Homogenates
were centrifuged at 800g for 15 minutes at 4◦C, supernatant
was later recentrifuged at 20 000g for 10 minutes. Following
the removal of the supernatant, the mildly swollen layer on
top of the mitochondrial pellet was removed with the gentle
addition of sucrose solution. Pellet was later prepared for
analyses by suspension with 1.2mL of 0.02M phosphate
buﬀer at pH 7.4.
2.4. Activity Analyses. MDA were measured spectrophoto-
metrically according to the thiobarbituric acid (TBA) meth-
od [16]. TAS, TOS, PON, and arylesterase activities were
measured using the commercial kit (Rel Assay Diagnostic)
Syncron LX autoanalyzer. OSI was calculated according to
the following formula: OSI: TOS/TASX100.
Catalase activity was determined by measuring the
amount of H2O2 decreased at 240nm wavelength according
to the method deﬁned by Beers and Sizer [17]. GST activities
were calculated spectrophotometrically at 340nm according
to the method deﬁned by Habig et al. [18].
2.5. Statistical Analysis. Statistical analysis was performed
using the Kruskal Wallis analysis (SPSS, 14.0). Paired com-
parisons were performed with Mann-Whitney U test, when
a P value of ≤0.05 was obtained. A P value of ≤0.05 was
considered signiﬁcant.
3. Results
In the comparison of parameters measured in control group
by tissue types as shown in Table 1 (lung, liver, kidney, and
heart),nosigniﬁcantdiﬀerencesweredeterminedintermsof
MDA and PON. Paired comparisons with Mann-Whitney U
test demonstrated that level of MDA was signiﬁcantly higher
in heart tissue compared to the lung and kidney tissues (P<
0.05),andPONactivitywassigniﬁcantlyhigherinthekidney
tissue compared to the liver and lung tissues (P<0.05).
Kruskal Wallis analysis was used to determine signiﬁcant
diﬀerencesbetweenthegroups,andnosigniﬁcantdiﬀerences
were determined in the paired comparison of other tissue
types (P>0.05).
No signiﬁcant diﬀerences were determined in terms of
MDA and TOS between the groups in the evaluation of
parameters measured in diabetic group by tissue types.
Paired comparisons with Mann-Whitney U test demon-
strated that MDA level of liver tissue was signiﬁcantly higher
compared to that of the heart tissue (P<0.05). TOS level
of liver tissue was signiﬁcantly higher compared to that of
the heart and lung tissues (P<0.05). Renal TOS level was
also signiﬁcantly higher compared to the lung and heart
(P<0.05). Kruskal Wallis analysis was used to determine
signiﬁcantdiﬀerencesbetweenthegroups,andnosigniﬁcant
diﬀerences were determined in the paired comparison of
other tissue types (P>0.05) (Table 1).
A signiﬁcant diﬀerence was determined in terms of TOS,
OSI (%), GST, and Catalase between the groups in the
evaluation of parameters measured in mitochondrial tissue
fractions by tissue types in the diabetic group, as shown in
Table 2. In the paired comparison of these groups with the
Mann-Whitney U test, TOS and OSI levels were signiﬁcantly
higher in the mitochondrial fraction of liver tissue compared
to the heart tissue and kidney tissue, respectively (P<0.05).
Catalase-speciﬁc activity in the mitochondrial fraction of
liver tissue was signiﬁcantly higher compared to that of the
mitochondrial fraction of lung tissue. GST-speciﬁc-activity
wasappointedtobesigniﬁcantlyhigherinthemitochondrial
fraction liver tissue compared to mitochondrial fractions of
alltissuetypes.KruskalWallisanalysiswasusedtodetermine
signiﬁcantdiﬀerencesbetweenthegroups,andnosigniﬁcant
diﬀerences were determined in the paired comparison of
other tissue types (P>0.05).
Signiﬁcant diﬀerence was determined in terms of MDA,
OSI (%) and Catalase between the groups in the evaluation
of parameters measured in mitochondrial tissue fractions
of control group by diﬀerent tissue types (Table 2). Paired
comparisons with Mann-Whitney U test in these groups
demonstrated that OSI (%) level was signiﬁcantly higher in
mitochondrial fraction of liver tissue compared to kidney
and heart tissues (P<0.05). Catalase-speciﬁc activity in
mitochondrial fraction of kidney tissue was signiﬁcantly
higher compared to that of lung tissue. MDA level was
determined to be signiﬁcantly higher in the mitochondrial
fraction of liver tissue compared to mitochondrial fractionsExperimental Diabetes Research 3
Table 1: Evaluation of parameters measured in both group by tissue types.
Measurement Lung X ± SL i v e r X ± S Kidney X ± S Heart X ± S
MDA (nmol/mL)
Control 3,81 ±1,1§ 3,22 ± 0,7 5,22 ± 0,8ξ 1,29 ± 0,4ξ
Diabetic 3,22 ± 3,1 9,01 ± 7,8∗ 3,30 ± 1,5 0,50 ± 0,4∗
T A S( m m o lt r o l o xE q u i v / L )
Control 0,423 ±0,54 0,406 ± 0,21 0,376 ± 0,10 0,143 ± 0,03
Diabetic 0,19 ± 0,06 0,53 ± 0,28 0,45 ± 0,28 0,18 ± 0,04
TOS (μmol H2O2 Equiv/L)
Control 7,75 ±10,4 4,46 ± 1,2 6,40 ± 2,4 2,53 ± 0,9
Diabetic 2,22 ± 0,03# 6,29 ± 1,05# 4,59 ± 0,78# 1,49 ± 0,6#
OS˙ I( % )
Control 16,83 ±2,35 13,12 ± 6,70 16,97 ± 4,12 17,35 ± 3,42
Diabetic 12,05 ± 3,4 15,82 ± 11,4 12,49 ± 6,99 8,07 ± 1,44
PON (U/L)
Control 4,33 ± 3,2∗ 4,33 ± 1,5∗ 9,33 ± 0,5∗ 7,66 ± 1,5
Diabetic 6,00 ± 3,0 6,00 ± 4,3 8,00 ± 1,0 7,33 ± 1,5
Arylesterase (U/L)
Control 4365,0 ±410,7 4347,6 ± 738,5 4093,3 ± 359,1 4068,3 ± 380,6
Diabetic 4785,0 ± 111,8 4088,3 ± 541,0 4350,0 ± 172,4 4249,0 ± 483,0
GST (U/mgPrt)
Control 0,0032 ±0,002 0,0547 ± 0,040 0,0073 ± 0,004 0,0062 ± 0,003
Diabetic 0,0011 ± 0,001 0,0238 ± 0,020 0,0020 ± 0,003 0,0173 ± 0,029
Catalase (U/mgPrt)
Control 0,545 ±0,07 0,1176 ± 0,04 0,0371 ± 0,02 0,0188 ± 0,01
Diabetic 0,012 ± 0,003 0,0665 ± 0,029 0,0381 ± 0,036 0,0488 ± 0,04
∗P = 0.05, §P = 0,03, #P = 0.01.
of all other tissue types. Additionally, MDA level of mito-
chondrial fraction of lung tissue was also signiﬁcantly higher
compared to the MDA levels in the mitochondrial fraction of
kidney and heart tissues (P<0.05). Kruskal Wallis analysis
was used to determine signiﬁcant diﬀerences between the
groups,andnosigniﬁcantdiﬀerencesweredeterminedinthe
paired comparison of other tissue types (P>0.05).
No signiﬁcant diﬀerences were determined between the
diabetic and control groups in the statistical analysis of
parameters measured in all tissue types (tissue-mitochondri-
al) (P>0.05).
4. Discussion
Male and female rats were equally distributed to each group
to prevent the inﬂuence of confounding factors including
sex. The most signiﬁcant increase in the level of MDA
among rats with chemically induced diabetes was observed
in the liver when the results were evaluated between diﬀerent
tissues and within the same group (Table 1). Studies on
rats with STZ-induced diabetes have demonstrated that
MDA levels were signiﬁcantly increased in the liver [19]
and kidney mitochondria [19, 20]. According to our results
this increase was limited to the liver; however it was not
statistically signiﬁcant. The increase in TOS in both liver
and mitochondrial fractions in the diabetic group led to an
increase also in the OSI. Although MDA, TOS, and OSI were
increased, these were not statistically signiﬁcant increases
compared to the control group (P>0.05). No signiﬁcant
diﬀerences were noted between the two groups, tissues and
mitochondrial fractions when levels of TAS were compared.
A signiﬁcant increase only in the catalase activity of
liver mitochondria of the diabetic group was noted in the
comparison of the antioxidative enzymes PON, arylesterase,
and catalase (P = 0.03). The lack of diﬀerence in OSI levels
in between the groups suggested us the contribution of the
increased catalase activity. A study on acute diabetic rats
has demonstrated that catalase activity is not altered [21];
howeveranothertime-dependentstudyhasdemonstratedan
increase in the ﬁrst week followed by a decrease compared to
thecontrols[22].Inthelongterm,thiswillaﬀecttheOSIand
trigger oxidative injury. Planning of a time-dependent study
is important to demonstrate the alterations in OSI.
On the other hand, in terms of the data of GST,
liver mitochondrial fraction was increased in the diabetic
group, although not statistically signiﬁcantly compared to
the controls. This increase in GST is in response to STZ
and causes a reﬂex in the detoxiﬁcation system. It is known
that medications and endogenous-exogenous chemical sub-
stances are ﬁrst metabolized by the liver microsomal oxidase4 Experimental Diabetes Research
Table 2: Evaluation of parameters measured in the mitochondrial fraction of both group by tissue types.
Measurement Lung X ± SL i v e r X ± S Kidney X ± S Heart X ± S
MDA (nmol/L)
Control 4,23 ± 0,59# 6,04 ± 0,12# 2,54 ± 0,67# 1,21 ± 0,29#
Diabetic 2,90 ± 2,00 6,21 ± 4,63 4,43 ± 3,81 1,61 ± 0,99
T A S( m m o lt r o l o xE q u i v / L )
Control 0,79 ± 0,86 0,69 ± 0,55 1,46 ± 0,32 0,83 ± 0,59
Diabetic 0,51 ± 0,10 2,11 ± 1,65 1,28 ± 0,20 0,42 ± 0,15
TOS (μmol H2O2 Equiv/L)
Control 8,83 ± 11,79 7,82 ± 9,31 2,27 ± 0,79 1,57 ± 1,28
Diabetic 1,87 ± 0,35 10,00 ± 7,09 2,19 ± 0,76 0,85 ± 0,33
OS˙ I( % )
Control 8,66 ± 5,03 16,10 ± 21,67§ 1,52 ± 0,28§ 1,82 ± 0,32§
Diabetic 3,84 ± 1,44 5,59 ± 2,15∗ 1,68 ± 0,22∗ 2,20 ± 1,0
PON (U/L)
Control 6,00 ± 2,00 11,66 ± 12,50 7,33 ± 2,08 8,00 ± 1,00
Diabetic 7,33 ± 0,57 10,66 ± 5,85 7,33 ± 1,52 9,66 ± 2,88
Arylesterase (U/L)
Control 5006,6 ± 742,0 4330,6 ± 951,4 4636,3 ± 210,7 3996,3 ± 183,9
Diabetic 3583,6 ± 1487,6 4460,6 ± 449,5 4348,0 ± 165,3 3996,6 ± 136,0
GST (U/mgPrt)
Control 0,0027 ± 0,001 0,0307 ± 0,016 0,0063 ± 0,004 0,0077 ± 0,005
Diabetic 0,0023 ± 0,0007 0,0272 ± 0,003 0,0038 ± 0,001 0,0087 ± 0,004
Catalase (U/mgPrt)
Control 0,0126 ± 0,004ξ 0,0655 ± 0,032 0,1005 ± 0,047ξ 0,0254 ± 0,02
Diabetic 0,0086 ± 0,003§ 0,0575 ± 0,024§ 0,0429 ± 0,0094 0,0266 ± 0,009
#P = 0.01, P = 0.02, §P = 0.03, ξP = 0.04, ∗P = 0.05.
systems leading to the formation of several toxic interme-
diate products. This is the phase 1 reaction needed for
the metabolism of xenobiotics. These toxic substances are
conjugated and transformed in to polar compounds that
dissolve in water in order to excrete in urine in phase 2
reactions. GST is one of the most important phase 2 systems
[23]. The increase in GST activity will both prevent the cells
from the toxic eﬀects of harmful compounds and prevent
the development of oxidative injury. The lack of diﬀerence in
terms of OSI in between the groups possibly resulted from
the increased GST activity. Although we did not ﬁnd any
other study investigating the relationship between GST and
diabetes, there is one study on the eﬀect of STC on GST. This
studyhassuggestedthatGSTactivitywasdecreased[24].The
lack of more studies on this topic is a limitation in terms of
the comparison of our results. Further studies on this topic
will be very important to remove the uncertainties, since the
reported result contradicts with ours.
Consequently, althoughpartial diﬀerences were observed
between the tissues within the same group, no statistically
signiﬁcant diﬀerence was determined between the tissues
andmitochondrialfractions.However,oxidativestressmight
develop in the long term in a chronic picture of diabetes and
lead to tissue injury in addition to reduction in catalase and
GST activity.
5. Conclusion
Consequently, although partial diﬀerences have been noted
in both oxidant/antioxidant systems and detoxiﬁcation en-
zyme (i.e., GST) activity in tissue and mitochondria of rats
with experimental diabetes, these diﬀerences are not statisti-
cally signiﬁcant compared to the control group. According to
our results, oxidative stress has not developed in acute dia-
betes induced by a chemical agent, suggesting that oxidative
stress might develop in long term and lead to tissue injury in
a chronic picture of diabetes.
References
[ 1 ]H .K i n g ,R .E .A u b e r t ,a n dW .H .H e r m a n ,“ G l o b a lb u r d e n
of diabetes, 1995—2025: prevalence, numerical estimates, and
projections,” Diabetes Care, vol. 21, no. 9, pp. 1414–1431,
1998.
[2] B. K. Tripathi and A. K. Srivastava, “Diabetes mellitus: com-
plications and therapeutics,” Medical Science Monitor, vol. 12,
no. 7, pp. RA130–RA147, 2006.
[3] P. J. Thornalley, “Glycation in diabetic neuropathy: char-
acteristics, consequences, causes, and therapeutic options,”
International Review of Neurobiology, vol. 50, pp. 37–57, 2002.
[4] A. F. Milano, “Diabetes mellitus and life insurance,” Journal of
Insurance Medicine, vol. 33, no. 1, pp. 50–103, 2001.Experimental Diabetes Research 5
[5] A. M. Vincent, J. W. Russell, P. Low, and E. L. Feldman,
“Oxidative stress in the pathogenesis of diabetic neuropathy,”
Endocrine Reviews, vol. 25, no. 4, pp. 612–628, 2004.
[6] R. Memisoˇ gullari, S. Taysi, E. Bakan, and I. Capoglu, “Antioxi-
dantstatusandlipidperoxidationintypeIIdiabetesmellitus,”
Cell Biochemistry and Function, vol. 21, no. 3, pp. 291–296,
2003.
[7] A. K. Mohamed, A. Bierhaus, S. Schiekofer, H. Tritschler, R.
Z i e g l e r ,a n dP .P .N a w r o t h ,“ T h er o l eo fo x i d a t i v es t r e s sa n d
NF-κB activation in late diabetic complications,” BioFactors,
vol. 10, no. 2-3, pp. 157–167, 1999.
[8] J. W. Baynes, “Role of oxidative stress in development of
complications in diabetes,” Diabetes, vol. 40, no. 4, pp. 405–
412, 1991.
[9] G. L. King and N. K. Banskota, “Mechanism of diabetic mi-
crovascular complications,” in Joslin’s Diabetes Mellitus,C .R .
Kahn and G. C. Weir, Eds., pp. 634–648, Lippincott Williams
& Wilkins, Philadelphia, Pa, USA, 30th edition, 1994.
[10] A. M. Armstrong, J. E. Chestnutt, M. J. Gormley, and I. S.
Young, “The eﬀect of dietary treatment on lipid peroxidation
and antioxidant status in newly diagnosed noninsulin depen-
dent diabetes,” Free Radical Biology and Medicine, vol. 21, no.
5, pp. 719–726, 1996.
[11] D. Giugliano, A. Ceriello, and G. Paolisso, “Oxidative stress
and diabetic vascular complications,” Diabetes Care, vol. 19,
no. 3, pp. 257–267, 1996.
[12] S. R. J. Maxwell, H. Thomason, D. Sandler et al., “Poor
glycaemiccontrolisassociatedwithreducedserumfreeradical
scavenging (antioxidant) activity in non-insulin-dependent
diabetes mellitus,” Annals of Clinical Biochemistry, vol. 34, no.
6, pp. 638–644, 1997.
[13] N. N. Orie, W. Zidek, and M. Tepel, “Increased intracellular
generation of reactive oxygen species in mononuclear leuko-
cytes from patients with diabetes mellitus type 2,” Experimen-
tal and Clinical Endocrinology and Diabetes, vol. 108, no. 3, pp.
175–180, 2000.
[14] S. R. Max, J. Garbus, and H. J. Wehman, “Simple procedure
for rapid isolation of functionally intact mitochondria from
human and rat skeletal muscle,” Analytical Biochemistry, vol.
46, no. 2, pp. 576–584, 1972.
[15] H. M. Mousa, Cyanide detoxiﬁcation in domestic fowl (Gallus
domesticus), Ph.D. thesis, University of London, London, UK,
1982.
[16] H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides
in animal tissues by thiobarbituric acid reaction,” Analytical
Biochemistry, vol. 95, no. 2, pp. 351–358, 1979.
[ 1 7 ]R .F .B e e r sJ r .a n dI .W .S i z e r ,“ As p e c t r o p h o t o m e t r i cm e t h o d
for measuring the breakdown of hydrogen peroxide by cata-
lase,” The Journal of Biological Chemistry, vol. 195, no. 1, pp.
133–140, 1952.
[18] W. H. Habig, M. J. Pabst, and W. B. Jakoby, “Glutathione
S transferases: the ﬁrst enzymatic step in mercapturic acid
formation,” The Journal of Biological Chemistry, vol. 249, no.
22, pp. 7130–7139, 1974.
[19] Y. Y. Jang, J. H. Song, Y. K. Shin, E. S. Han, and C. S. Lee,
“Protective eﬀect of boldine on oxidative mitochondrial dam-
age in streptozotocin-induced diabetic rats,” Pharmacological
Research, vol. 42, no. 4, pp. 361–371, 2000.
[20] X.-F. Zhang and B. K.-H. Tan, “Antihyperglycaemic and anti-
oxidant properties of Andrographis paniculata in normal and
diabetic rats,” Clinical and Experimental Pharmacology and
Physiology, vol. 27, no. 5-6, pp. 358–363, 2000.
[21] K. Volkovova, V. Chorvathova, M. Jurcovicova, L. Koszeghy-
ova, and P. Bobek, “Antioxidative state of the myocardium and
kidneys in acute diabetic rats,” Physiological Research, vol. 42,
no. 4, pp. 251–255, 1993.
[22] R. Kakar, S. V. Mantha, J. Radhi, K. Prasad, and J. Karla, “Anti-
oxidant defens system in diabetic kidney: a time course study,”
Life Sciences, vol. 60, no. 9, pp. 667–679, 1997.
[ 2 3 ]R .K .M u r r a y ,P .A .M a y e s ,D .K .G r a n n e r ,a n dV .W .R o d w e l l ,
Harper’s Biochemistry, Section in Xenobiotics Metabolism,
Apleton & Longe, Norwalk, Conn, USA, 22nd edition, 1990.
[24] C. Agius and A. S. Gidari, “Eﬀect of streptozotocin on the
glutathione S-transferase of mouse liver cytosol,” Biochemical
Pharmacology, vol. 34, no. 6, pp. 811–819, 1985.